Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	acetyl-CoA carboxylase activity	ACACB ACACA	9.53e-07	2	20	2	GO:0003989
GeneOntologyMolecularFunction	biotin binding	ACACB ACACA	1.43e-05	6	20	2	GO:0009374
GeneOntologyMolecularFunction	CoA carboxylase activity	ACACB ACACA	1.43e-05	6	20	2	GO:0016421
GeneOntologyMolecularFunction	ligase activity, forming carbon-carbon bonds	ACACB ACACA	2.00e-05	7	20	2	GO:0016885
GeneOntologyMolecularFunction	monocarboxylic acid binding	ACACB ACACA	5.07e-03	107	20	2	GO:0033293
GeneOntologyBiologicalProcess	malonyl-CoA biosynthetic process	ACACB ACACA	1.19e-06	2	23	2	GO:2001295
GeneOntologyBiologicalProcess	malonyl-CoA metabolic process	ACACB ACACA	1.78e-05	6	23	2	GO:2001293
GeneOntologyBiologicalProcess	thioester biosynthetic process	ACACB ELOVL6 ACACA	2.16e-05	49	23	3	GO:0035384
GeneOntologyBiologicalProcess	acyl-CoA biosynthetic process	ACACB ELOVL6 ACACA	2.16e-05	49	23	3	GO:0071616
GeneOntologyBiologicalProcess	sulfur compound biosynthetic process	ACACB ELOVL6 DSEL ACACA	4.18e-05	178	23	4	GO:0044272
GeneOntologyBiologicalProcess	nucleoside bisphosphate biosynthetic process	ACACB ELOVL6 ACACA	4.18e-05	61	23	3	GO:0033866
GeneOntologyBiologicalProcess	ribonucleoside bisphosphate biosynthetic process	ACACB ELOVL6 ACACA	4.18e-05	61	23	3	GO:0034030
GeneOntologyBiologicalProcess	purine nucleoside bisphosphate biosynthetic process	ACACB ELOVL6 ACACA	4.18e-05	61	23	3	GO:0034033
GeneOntologyBiologicalProcess	carbohydrate derivative biosynthetic process	ACACB ST8SIA1 ELOVL6 GALNT2 DSEL ACACA	1.21e-04	736	23	6	GO:1901137
GeneOntologyBiologicalProcess	monocarboxylic acid biosynthetic process	ACACB ELOVL6 DSEL ACACA	1.81e-04	260	23	4	GO:0072330
GeneOntologyBiologicalProcess	lipid biosynthetic process	ACACB LSS PI4KAP2 ST8SIA1 ELOVL6 ACACA	2.09e-04	813	23	6	GO:0008610
GeneOntologyBiologicalProcess	thioester metabolic process	ACACB ELOVL6 ACACA	2.35e-04	109	23	3	GO:0035383
GeneOntologyBiologicalProcess	acyl-CoA metabolic process	ACACB ELOVL6 ACACA	2.35e-04	109	23	3	GO:0006637
GeneOntologyBiologicalProcess	fatty-acyl-CoA biosynthetic process	ELOVL6 ACACA	4.10e-04	27	23	2	GO:0046949
GeneOntologyBiologicalProcess	nucleoside bisphosphate metabolic process	ACACB ELOVL6 ACACA	5.11e-04	142	23	3	GO:0033865
GeneOntologyBiologicalProcess	ribonucleoside bisphosphate metabolic process	ACACB ELOVL6 ACACA	5.11e-04	142	23	3	GO:0033875
GeneOntologyBiologicalProcess	purine nucleoside bisphosphate metabolic process	ACACB ELOVL6 ACACA	5.11e-04	142	23	3	GO:0034032
GeneOntologyBiologicalProcess	sulfur compound metabolic process	ACACB ELOVL6 DSEL ACACA	6.54e-04	365	23	4	GO:0006790
GeneOntologyBiologicalProcess	carboxylic acid biosynthetic process	ACACB ELOVL6 DSEL ACACA	7.17e-04	374	23	4	GO:0046394
GeneOntologyBiologicalProcess	organic acid biosynthetic process	ACACB ELOVL6 DSEL ACACA	7.39e-04	377	23	4	GO:0016053
GeneOntologyBiologicalProcess	small molecule biosynthetic process	ACACB LSS ELOVL6 DSEL ACACA	7.67e-04	676	23	5	GO:0044283
GeneOntologyBiologicalProcess	acetyl-CoA metabolic process	ACACB ACACA	8.60e-04	39	23	2	GO:0006084
GeneOntologyBiologicalProcess	amide biosynthetic process	ACACB ELOVL6 ACACA	8.93e-04	172	23	3	GO:0043604
GeneOntologyBiologicalProcess	fatty-acyl-CoA metabolic process	ELOVL6 ACACA	9.97e-04	42	23	2	GO:0035337
GeneOntologyBiologicalProcess	fatty acid biosynthetic process	ACACB ELOVL6 ACACA	1.21e-03	191	23	3	GO:0006633
GeneOntologyBiologicalProcess	fatty acid derivative biosynthetic process	ELOVL6 ACACA	1.52e-03	52	23	2	GO:1901570
GeneOntologyBiologicalProcess	carbohydrate derivative metabolic process	ACACB ST8SIA1 ELOVL6 GALNT2 DSEL ACACA	1.83e-03	1226	23	6	GO:1901135
GeneOntologyBiologicalProcess	myoblast fusion	DOCK2 CACNA1S	1.89e-03	58	23	2	GO:0007520
GeneOntologyBiologicalProcess	protein homooligomerization	ACACB KCTD6 ACACA	1.91e-03	224	23	3	GO:0051260
GeneOntologyBiologicalProcess	purine ribonucleotide biosynthetic process	ACACB ELOVL6 ACACA	2.11e-03	232	23	3	GO:0009152
GeneOntologyBiologicalProcess	ribonucleotide biosynthetic process	ACACB ELOVL6 ACACA	2.52e-03	247	23	3	GO:0009260
GeneOntologyBiologicalProcess	ribose phosphate biosynthetic process	ACACB ELOVL6 ACACA	2.69e-03	253	23	3	GO:0046390
GeneOntologyCellularComponent	T cell receptor complex	TRB TRBV25-1 TRAV1-2 TRAV1-1	2.34e-05	163	22	4	GO:0042101
GeneOntologyCellularComponent	plasma membrane signaling receptor complex	TRB TRBV25-1 TRAV1-2 TRAV1-1	4.45e-04	350	22	4	GO:0098802
GeneOntologyCellularComponent	plasma membrane protein complex	CACNA1S TRB TRBV25-1 TRAV1-2 TRAV1-1	1.14e-03	785	22	5	GO:0098797
GeneOntologyCellularComponent	receptor complex	TRB TRBV25-1 TRAV1-2 TRAV1-1	2.90e-03	581	22	4	GO:0043235
GeneOntologyCellularComponent	membrane protein complex	CACNA1S TRB TRBV25-1 TRAV1-2 TRAV1-1 ELOVL6	3.68e-03	1498	22	6	GO:0098796
Domain	AcCoA_COase_cen	ACACB ACACA	9.80e-07	2	19	2	IPR013537
Domain	ACC_central	ACACB ACACA	9.80e-07	2	19	2	PF08326
Domain	Carboxyl_trans	ACACB ACACA	5.88e-06	4	19	2	PF01039
Domain	COA_CT_N	ACACB ACACA	5.88e-06	4	19	2	IPR011762
Domain	COA_CT_C	ACACB ACACA	5.88e-06	4	19	2	IPR011763
Domain	COA_CT_CTER	ACACB ACACA	5.88e-06	4	19	2	PS50989
Domain	Carboxyl_trans	ACACB ACACA	5.88e-06	4	19	2	IPR000022
Domain	COA_CT_NTER	ACACB ACACA	5.88e-06	4	19	2	PS50980
Domain	Biotin_COase_C	ACACB ACACA	9.79e-06	5	19	2	IPR005482
Domain	Biotin_BS	ACACB ACACA	9.79e-06	5	19	2	IPR001882
Domain	Biotin_carb_C	ACACB ACACA	9.79e-06	5	19	2	SM00878
Domain	Biotin_carb_C	ACACB ACACA	9.79e-06	5	19	2	PF02785
Domain	Biotin_carboxylation_dom	ACACB ACACA	9.79e-06	5	19	2	IPR011764
Domain	BIOTIN	ACACB ACACA	9.79e-06	5	19	2	PS00188
Domain	CPSASE_1	ACACB ACACA	9.79e-06	5	19	2	PS00866
Domain	BC	ACACB ACACA	9.79e-06	5	19	2	PS50979
Domain	Rudment_hybrid_motif	ACACB ACACA	1.47e-05	6	19	2	IPR011054
Domain	CPSASE_2	ACACB ACACA	1.47e-05	6	19	2	PS00867
Domain	CbamoylP_synth_lsu-like_ATP-bd	ACACB ACACA	2.05e-05	7	19	2	IPR005479
Domain	BC-like_N	ACACB ACACA	2.05e-05	7	19	2	IPR005481
Domain	Biotin_carb_N	ACACB ACACA	2.05e-05	7	19	2	PF00289
Domain	CPSase_L_D2	ACACB ACACA	2.05e-05	7	19	2	PF02786
Domain	Biotin_lipoyl	ACACB ACACA	3.51e-05	9	19	2	PF00364
Domain	Biotin_lipoyl	ACACB ACACA	4.39e-05	10	19	2	IPR000089
Domain	BIOTINYL_LIPOYL	ACACB ACACA	4.39e-05	10	19	2	PS50968
Domain	Single_hybrid_motif	ACACB ACACA	6.43e-05	12	19	2	IPR011053
Domain	-	ACACB ACACA	7.60e-05	13	19	2	3.40.50.20
Domain	ATP-grasp	ACACB ACACA	8.86e-05	14	19	2	IPR011761
Domain	PreATP-grasp_dom	ACACB ACACA	8.86e-05	14	19	2	IPR016185
Domain	ATP_GRASP	ACACB ACACA	8.86e-05	14	19	2	PS50975
Domain	-	ACACB ACACA	1.02e-04	15	19	2	3.30.1490.20
Domain	-	ACACB ACACA	1.49e-04	18	19	2	3.30.470.20
Domain	ATP_grasp_subdomain_1	ACACB ACACA	1.49e-04	18	19	2	IPR013815
Domain	-	ACACB ACACA	2.04e-04	21	19	2	3.90.226.10
Domain	ClpP/crotonase-like_dom	ACACB ACACA	2.04e-04	21	19	2	IPR029045
Domain	ATP_grasp_subdomain_2	ACACB ACACA	4.48e-04	31	19	2	IPR013816
Domain	-	EIF2B5 GALNT2	3.03e-03	81	19	2	3.90.550.10
Domain	Nucleotide-diphossugar_trans	EIF2B5 GALNT2	3.56e-03	88	19	2	IPR029044
Pathway	REACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP	ACACB LSS ELOVL6 ACACA	2.02e-07	42	18	4	M27172
Pathway	REACTOME_REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF	ACACB LSS ELOVL6 ACACA	6.09e-07	55	18	4	M27001
Pathway	REACTOME_METABOLISM_OF_STEROIDS	ACACB LSS ELOVL6 ACACA	3.72e-05	154	18	4	M27832
Pathway	REACTOME_CHREBP_ACTIVATES_METABOLIC_GENE_EXPRESSION	ACACB ACACA	4.29e-05	8	18	2	M26991
Pathway	WP_BIOTIN_METABOLISM_INCLUDING_IMDS	ACACB ACACA	5.51e-05	9	18	2	M40064
Pathway	REACTOME_BIOTIN_TRANSPORT_AND_METABOLISM	ACACB ACACA	8.41e-05	11	18	2	M27086
Pathway	REACTOME_BIOTIN_TRANSPORT_AND_METABOLISM	ACACB ACACA	8.41e-05	11	18	2	MM14764
Pathway	REACTOME_CARNITINE_METABOLISM	ACACB ACACA	1.39e-04	14	18	2	M27098
Pathway	REACTOME_CARNITINE_METABOLISM	ACACB ACACA	1.39e-04	14	18	2	MM14788
Pathway	WP_HEREDITARY_LEIOMYOMATOSIS_AND_RENAL_CELL_CARCINOMA_PATHWAY	ACACB ACACA	2.89e-04	20	18	2	M39751
Pathway	WP_FATTY_ACID_BIOSYNTHESIS	ACACB ACACA	3.50e-04	22	18	2	M39440
Pathway	WP_FATTY_ACID_BIOSYNTHESIS	ACACB ACACA	3.83e-04	23	18	2	MM15885
Pathway	REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS	ELOVL6 ACACA	7.47e-04	32	18	2	MM15446
Pathway	KEGG_PROPANOATE_METABOLISM	ACACB ACACA	7.94e-04	33	18	2	M4086
Pathway	REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS	ELOVL6 ACACA	9.99e-04	37	18	2	M729
Pathway	KEGG_PYRUVATE_METABOLISM	ACACB ACACA	1.17e-03	40	18	2	M7934
Pathway	REACTOME_FATTY_ACID_METABOLISM	ACACB ELOVL6 ACACA	1.23e-03	170	18	3	MM15573
Pathway	REACTOME_FATTY_ACID_METABOLISM	ACACB ELOVL6 ACACA	1.36e-03	176	18	3	M27854
Pathway	WP_NEURODEGENERATION_WITH_BRAIN_IRON_ACCUMULATION_NBIA_SUBTYPES_PATHWAY	WIPI1 ACACA	1.41e-03	44	18	2	M39602
Pathway	WP_AMPACTIVATED_PROTEIN_KINASE_SIGNALING	ACACB ACACA	3.24e-03	67	18	2	M39630
Pathway	WP_STEROL_REGULATORY_ELEMENTBINDING_PROTEINS_SREBP_SIGNALING	LSS ACACA	3.63e-03	71	18	2	M39395
Pathway	WP_LEPTIN_SIGNALING	ACACB ACACA	4.15e-03	76	18	2	M39491
Pubmed	Blocking AMPK signalling to acetyl-CoA carboxylase increases cisplatin-induced acute kidney injury and suppresses the benefit of metformin.	ACACB ACACA	4.18e-07	2	23	2	36076520
Pubmed	De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells.	ACACB ACACA	4.18e-07	2	23	2	25282359
Pubmed	AMPK-dependent inhibitory phosphorylation of ACC is not essential for maintaining myocardial fatty acid oxidation.	ACACB ACACA	4.18e-07	2	23	2	25001074
Pubmed	Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.	ACACB ACACA	4.18e-07	2	23	2	27693630
Pubmed	AMPK signaling to acetyl-CoA carboxylase is required for fasting- and cold-induced appetite but not thermogenesis.	ACACB ACACA	4.18e-07	2	23	2	29433631
Pubmed	Structure and regulation of acetyl-CoA carboxylase genes of metazoa.	ACACB ACACA	4.18e-07	2	23	2	15749055
Pubmed	The subcellular localization of acetyl-CoA carboxylase 2.	ACACB ACACA	4.18e-07	2	23	2	10677481
Pubmed	Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival.	ACACB ACACA	4.18e-07	2	23	2	28290443
Pubmed	Effects of PKB/Akt inhibitors on insulin-stimulated lipogenesis and phosphorylation state of lipogenic enzymes in white adipose tissue.	ACACB ACACA	4.18e-07	2	23	2	32215608
Pubmed	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.	ACACB ACACA	4.18e-07	2	23	2	30244972
Pubmed	Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription.	ACACB ACACA	4.18e-07	2	23	2	20139635
Pubmed	Activity and structure of human acetyl-CoA carboxylase targeted by a specific inhibitor.	ACACB ACACA	4.18e-07	2	23	2	29772612
Pubmed	Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells.	ACACB ACACA	4.18e-07	2	23	2	28081256
Pubmed	Susceptibility of podocytes to palmitic acid is regulated by fatty acid oxidation and inversely depends on acetyl-CoA carboxylases 1 and 2.	ACACB ACACA	4.18e-07	2	23	2	24338821
Pubmed	Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin.	ACACB ACACA	4.18e-07	2	23	2	29976587
Pubmed	Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.	ACACB ACACA	4.18e-07	2	23	2	26976583
Pubmed	Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation.	ACACB ACACA	4.18e-07	2	23	2	24944901
Pubmed	ATP-citrate lyase deficiency in the mouse.	ACACB ELOVL6 ACACA	4.44e-07	23	23	3	14662765
Pubmed	Differential activation of recombinant human acetyl-CoA carboxylases 1 and 2 by citrate.	ACACB ACACA	1.25e-06	3	23	2	18455495
Pubmed	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.	ACACB ACACA	1.25e-06	3	23	2	28877461
Pubmed	AMPK activation by SC4 inhibits noradrenaline-induced lipolysis and insulin-stimulated lipogenesis in white adipose tissue.	ACACB ACACA	1.25e-06	3	23	2	34668531
Pubmed	Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis.	ACACB ACACA	1.25e-06	3	23	2	20457939
Pubmed	Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.	ACACB ACACA	1.25e-06	3	23	2	31990961
Pubmed	AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation.	ACACB ACACA	1.25e-06	3	23	2	30018077
Pubmed	Macrophage acetyl-CoA carboxylase regulates acute inflammation through control of glucose and lipid metabolism.	ACACB ACACA	1.25e-06	3	23	2	36417534
Pubmed	The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.	ACACB ACACA	1.25e-06	3	23	2	27381369
Pubmed	Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.	ACACB ACACA	1.25e-06	3	23	2	17210641
Pubmed	Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels.	ACACB ACACA	1.25e-06	3	23	2	19846279
Pubmed	Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.	ACACB ACACA	1.25e-06	3	23	2	18031993
Pubmed	Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas.	ACACB ACACA	1.25e-06	3	23	2	17521700
Pubmed	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.	ACACB ACACA	1.25e-06	3	23	2	28768177
Pubmed	Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin.	ACACB ACACA	2.51e-06	4	23	2	24185692
Pubmed	Crystal structure of Spot 14, a modulator of fatty acid synthesis.	ACACB ACACA	2.51e-06	4	23	2	20952656
Pubmed	Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability.	ACACB ACACA	2.51e-06	4	23	2	38447582
Pubmed	Cullin 1 (CUL1) Promotes Primary Ciliogenesis through the Induction of Ubiquitin-Proteasome-Dependent Dvl2 Degradation.	CACNA1S TRB ATP9B ACACA	2.91e-06	152	23	4	34299191
Pubmed	Acetyl-CoA carboxylase 1 is a suppressor of the adipocyte thermogenic program.	ACACB ACACA	4.18e-06	5	23	2	37163372
Pubmed	Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss.	ACACB ACACA	4.18e-06	5	23	2	32694673
Pubmed	TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism.	ACACB ACACA	4.18e-06	5	23	2	16794074
Pubmed	BCAR1 promotes proliferation and cell growth in lung adenocarcinoma via upregulation of POLR2A.	SUGP1 DOCK2 LSS EIF2B5 GALNT2	6.97e-06	419	23	5	33001583
Pubmed	The AMPK-HOXB9-KRAS axis regulates lung adenocarcinoma growth in response to cellular energy alterations.	ACACB ACACA	1.17e-05	8	23	2	36001969
Pubmed	SIRT1 regulates Tat-induced HIV-1 transactivation through activating AMP-activated protein kinase.	ACACB ACACA	1.88e-05	10	23	2	19720090
Pubmed	HDAC1/NFκB pathway is involved in curcumin inhibiting of Tat-mediated long terminal repeat transactivation.	ACACB ACACA	2.75e-05	12	23	2	21344388
Pubmed	AMP-activated protein kinase (AMPK) activity is not required for neuronal development but regulates axogenesis during metabolic stress.	ACACB ACACA	2.75e-05	12	23	2	21436046
Pubmed	Mtu1-Mediated Thiouridine Formation of Mitochondrial tRNAs Is Required for Mitochondrial Translation and Is Involved in Reversible Infantile Liver Injury.	ACACB ELOVL6 ACACA	3.15e-05	93	23	3	27689697
Pubmed	A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia.	SUGP1 GALNT2	7.10e-05	19	23	2	19656773
Pubmed	AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development.	ACACB ACACA	8.72e-05	21	23	2	19217427
Pubmed	Genetic variability of the fatty acid synthase pathway is not associated with prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).	ACACB ACACA	9.59e-05	22	23	2	20965718
Pubmed	Biosynthesis of triacylglycerols.	ELOVL6 ACACA	1.56e-04	28	23	2	8944226
Pubmed	WWP2 is an E3 ubiquitin ligase for PTEN.	ACACB ACACA	1.68e-04	29	23	2	21532586
Pubmed	Inceptor counteracts insulin signalling in β-cells to control glycaemia.	ACACB ACACA	2.32e-04	34	23	2	33505018
Pubmed	LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation.	ACACB ACACA	2.32e-04	34	23	2	26378152
Pubmed	Proteomic analysis of HIV-1 Gag interacting partners using proximity-dependent biotinylation.	ACACB ACACA	3.54e-04	42	23	2	26362536
Pubmed	Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance.	ACACB DOCK2 ACACA	4.36e-04	226	23	3	31452512
Pubmed	Genetic variants influencing circulating lipid levels and risk of coronary artery disease.	SUGP1 GALNT2	4.83e-04	49	23	2	20864672
Pubmed	Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations.	LSS ELOVL6 ACACA	5.84e-04	250	23	3	18660489
Pubmed	Common variants at 30 loci contribute to polygenic dyslipidemia.	SUGP1 GALNT2	5.86e-04	54	23	2	19060906
Interaction	CDK17 interactions	ACACB SUGP1 ACACA	3.20e-05	63	20	3	int:CDK17
Cytoband	14q11	TRAV1-2 TRAV1-1	2.00e-03	132	23	2	14q11
Cytoband	7q34	TRB TRBV25-1	3.16e-03	167	23	2	7q34
GeneFamily	T cell receptor beta locus at 7q34	TRB TRBV25-1	1.46e-03	87	12	2	372
GeneFamily	T-cell receptor alpha locus at 14q11.2	TRAV1-2 TRAV1-1	2.63e-03	117	12	2	371
Coexpression	HORTON_SREBF_TARGETS	LSS ELOVL6 ACACA	7.61e-07	24	20	3	MM1329
Coexpression	HORTON_SREBF_TARGETS	LSS ELOVL6 ACACA	7.61e-07	24	20	3	M3009
Coexpression	GSE17186_NAIVE_VS_CD21LOW_TRANSITIONAL_BCELL_CORD_BLOOD_UP	DOCK2 ELOVL6 GALNT2 DSEL	1.45e-05	200	20	4	M7175
Coexpression	GUO_TARGETS_OF_IRS1_AND_IRS2	LSS GALNT2 ACACA	5.35e-05	97	20	3	MM1318
Coexpression	GUO_TARGETS_OF_IRS1_AND_IRS2	LSS GALNT2 ACACA	5.35e-05	97	20	3	M2434
ToppCell	COVID-19_Moderate-MAIT\|World / disease group, cell group and cell class	TRAV1-2 ELOVL6 DSEL	7.42e-05	160	23	3	bf73c5fe87c1f243edec17d7a2c30fae5e2cfd6b
ToppCell	droplet-Liver-HEPATOCYTES-1m-Epithelial-Hepatocyte_(Pericentral)\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHDH ELOVL6 ACACA	7.42e-05	160	23	3	c42bcc6c7d113f0db43febb088b75ca4ac7cb7a3
ToppCell	droplet-Liver-HEPATOCYTES-1m-Epithelial-Hepatocyte_(Pericentral_and_Periportal)\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACACB ELOVL6 ACACA	8.13e-05	165	23	3	d449a568664a81d9b5538e8f409301448a32ac37
ToppCell	droplet-Lung-1m-Hematologic-myeloid-plasmacytoid_dendritic_cell\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CHDH ST8SIA1 ELOVL6	8.27e-05	166	23	3	1ca888ae8168707493f19ee52a89d7c70e6cb51d
ToppCell	droplet-Lung-LUNG-1m-Myeloid-plasmacytoid_dendritic_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHDH ST8SIA1 ELOVL6	8.27e-05	166	23	3	6e6075d0c913e2516083f6dcab21d5878bcef7a4
ToppCell	droplet-Lung-LUNG-1m-Myeloid-Plasmacytoid_Dendritic\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHDH ST8SIA1 ELOVL6	8.27e-05	166	23	3	4fbe44e0aea197893614cd55f83119aa0f73ee53
ToppCell	droplet-Lung-1m-Hematologic-myeloid-plasmacytoid_dendritic_cell-plasmacytoid_dendritic\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CHDH ST8SIA1 ELOVL6	8.27e-05	166	23	3	4cba4ca1aa2321b9ef7cd230932b890d2434a252
ToppCell	droplet-Liver-HEPATOCYTES-1m-Epithelial-hepatocyte\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHDH ELOVL6 ACACA	8.57e-05	168	23	3	073b53d4cee6bc8c5c6fce51cf6cd9c316478f69
ToppCell	droplet-Liver-HEPATOCYTES-1m-Epithelial\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHDH ELOVL6 ACACA	8.57e-05	168	23	3	b98af4043dfa5dfa4413e482879fad88de484675
ToppCell	droplet-Liver-HEPATOCYTES-1m\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHDH ELOVL6 ACACA	8.72e-05	169	23	3	7785cab967a33560830c394c918d6ce625103858
ToppCell	droplet-Liver-HEPATOCYTES\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHDH ELOVL6 ACACA	8.72e-05	169	23	3	f195467438c589f87224bde7da720dea072d110c
ToppCell	RA-11._Adipocyte\|RA / Chamber and Cluster_Paper	ACACB ELOVL6 ACACA	1.05e-04	180	23	3	d48a3d27357f7d184132a6805950f93080146b59
ToppCell	facs-Marrow-T-cells-3m-Hematologic\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1S LSS WIPI1	1.07e-04	181	23	3	57f0cc749ae8b6a3d77e2af31f9a6e4739c57049
ToppCell	facs-Marrow-T-cells-3m-Hematologic-hematopoietic_stem_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1S LSS WIPI1	1.07e-04	181	23	3	d01b35cc2fc57991a35be6a06cb7351fbabd9a11
ToppCell	LA-11._Adipocyte\|World / Chamber and Cluster_Paper	ACACB ELOVL6 ACACA	1.10e-04	183	23	3	b177be283e1553fb1f69a346f1ba79ad00297fa2
ToppCell	facs-Marrow-T-cells-3m-Hematologic-Unknown_Progenitor\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1S LSS WIPI1	1.10e-04	183	23	3	b0b835f3b1de1bd46a47e1b805aa8994cd3a4e3e
ToppCell	RA-11._Adipocyte\|World / Chamber and Cluster_Paper	ACACB ELOVL6 ACACA	1.20e-04	188	23	3	4dac9d636e5cad4cda540b93d4bfed6b5732c880
ToppCell	control-Myeloid-Mast_cell\|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	CHDH ST8SIA1 ELOVL6	1.25e-04	191	23	3	afebdc59a1f884ce3f2f5fe040e16b0e95e4e7c5
Computational	Steroid hormone receptors and binding proteins.	ACACB ACACA	5.03e-04	26	14	2	MODULE_404
Drug	Fatty Acids, Essential	ACACB LSS ELOVL6 ACACA	1.91e-07	59	20	4	ctd:D005228
Drug	taurine-ursodeoxycholate conjugate	ACACB ELOVL6 ACACA	8.59e-06	46	20	3	ctd:C030141
Drug	6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one	ACACB ACACA	1.10e-05	6	20	2	ctd:C438505
Drug	monensin; Up 200; 10.9uM; MCF7; HT_HG-U133A_EA	LSS WIPI1 ELOVL6 ACACA	1.32e-05	170	20	4	1105_UP
Drug	Adenosine 5'-monophosphate monohydrate [18422-05-4]; Down 200; 11uM; HL60; HG-U133A	SUGP1 ATP9B GALNT2 ACACA	1.97e-05	188	20	4	1622_DN
Drug	Erythromycin	LSS WIPI1 ACACA	2.12e-05	62	20	3	ctd:D004917
Drug	chlorpromazine hydrochloride; Down 200; 1uM; PC3; HT_HG-U133A	ACACB SUGP1 ATP9B GALNT2	2.23e-05	194	20	4	1217_DN
Drug	Norfloxacin [70458-96-7]; Down 200; 12.6uM; PC3; HT_HG-U133A	SUGP1 ATP9B WIPI1 ELOVL6	2.23e-05	194	20	4	7283_DN
Drug	Clemizole hydrochloride [1163-36-6]; Up 200; 11uM; HL60; HT_HG-U133A	CLDN18 LSS ELOVL6 ACACA	2.32e-05	196	20	4	2339_UP
Drug	Disopyramide [3737-09-5]; Down 200; 11.8uM; PC3; HT_HG-U133A	ACACB SUGP1 ELOVL6 GALNT2	2.36e-05	197	20	4	7276_DN
Drug	Clomipramine hydrochloride [17321-77-6]; Down 200; 11.4uM; HL60; HG-U133A	ATP9B GALNT2 AZIN1 ACACA	2.41e-05	198	20	4	1566_DN
Drug	Amiloride hydrochloride dihydrate [17440-83-4]; Up 200; 13.2uM; MCF7; HT_HG-U133A	SUGP1 CACNA1S LSS ATP9B	2.51e-05	200	20	4	4109_UP
Drug	Biotin	ACACB ACACA	2.63e-05	9	20	2	DB00121
Drug	pyrroloquinoline quinone	CHDH EIF2B5 ELOVL6	2.68e-05	67	20	3	CID000001024
Drug	norketamine	CHDH DSEL	4.01e-05	11	20	2	CID000123767
Drug	isosteviol	ACACB ACACA	4.81e-05	12	20	2	ctd:C515747
Drug	Fatty Acids, Omega-3	ACACB ELOVL6 ACACA	8.36e-05	98	20	3	ctd:D015525
Drug	trifluoroacetic anhydride	CHDH DSEL	9.89e-05	17	20	2	CID000009845
Drug	Zimeldine	LSS WIPI1	9.89e-05	17	20	2	ctd:D015031
Drug	TO-901317	ACACB ELOVL6 ACACA	1.06e-04	106	20	3	ctd:C423915
Drug	Sotalol	LSS WIPI1	1.11e-04	18	20	2	ctd:D013015
Drug	4-methylumbelliferyl-beta-D-xyloside	ST8SIA1 ACACA	1.52e-04	21	20	2	CID000092229
Drug	AC1L1QCE	CHDH ACACA	1.68e-04	22	20	2	CID000008135
Drug	trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride	LSS WIPI1	2.00e-04	24	20	2	ctd:D001371
Drug	Flecainide	LSS WIPI1	2.35e-04	26	20	2	ctd:D005424
Drug	Pf-5	SUGP1 ACACA	2.35e-04	26	20	2	CID000024295
Drug	heparin pentasaccharide	SUGP1 EIF2B5 AZIN1	2.61e-04	144	20	3	CID000444410
Drug	Perhexiline	LSS WIPI1	2.93e-04	29	20	2	ctd:D010480
Drug	thioridazine hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA	SUGP1 LSS WIPI1	3.30e-04	156	20	3	1010_UP
Drug	Pentamidine	LSS WIPI1	3.81e-04	33	20	2	ctd:D010419
Drug	Mometasone furoate [83919-23-7]; Up 200; 7.6uM; HL60; HG-U133A	SUGP1 WIPI1 ACACA	4.62e-04	175	20	3	1746_UP
Drug	Thioridazine	LSS WIPI1	4.79e-04	37	20	2	ctd:D013881
Drug	lupenol	LSS ELOVL6	4.79e-04	37	20	2	CID000073040
Drug	Eburnamonine (-) [4880-88-0]; Up 200; 13.6uM; PC3; HT_HG-U133A	MAP3K20 LSS ATP9B	5.18e-04	182	20	3	7154_UP
Drug	compound 21	LSS ACACA	5.60e-04	40	20	2	CID005312128
Drug	Nifuroxazide [965-52-6]; Down 200; 14.6uM; HL60; HT_HG-U133A	MAP3K20 LSS ATP9B	5.70e-04	188	20	3	2490_DN
Drug	Dietary Carbohydrates	ACACB GALNT2 ACACA	5.78e-04	189	20	3	ctd:D004040
Drug	17-AAG; Down 200; 1uM; HL60; HT_HG-U133A	SUGP1 LSS ELOVL6	5.78e-04	189	20	3	1159_DN
Drug	Budesonide [51333-22-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	SUGP1 LSS ATP9B	5.87e-04	190	20	3	2866_DN
Drug	Nifuroxazide [965-52-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A	MAP3K20 SUGP1 LSS	5.96e-04	191	20	3	2850_DN
Drug	Chlorpromazine hydrochloride [69-09-0]; Up 200; 11.2uM; HL60; HT_HG-U133A	LSS WIPI1 ACACA	6.15e-04	193	20	3	1864_UP
Drug	Etifenin [63245-28-3]; Down 200; 12.4uM; HL60; HT_HG-U133A	ACACB SUGP1 GALNT2	6.15e-04	193	20	3	2477_DN
Drug	Diethylstilbestrol [56-53-1]; Up 200; 15uM; MCF7; HT_HG-U133A	SUGP1 LSS WIPI1	6.15e-04	193	20	3	3429_UP
Drug	rosiglitazone; Down 200; 10uM; PC3; HT_HG-U133A	ACACB SUGP1 ATP9B	6.15e-04	193	20	3	1233_DN
Drug	Solasodine [126-17-0]; Down 200; 9.6uM; PC3; HT_HG-U133A	SUGP1 WIPI1 ELOVL6	6.15e-04	193	20	3	4305_DN
Drug	Nortriptyline hydrochloride [894-71-3]; Up 200; 13.4uM; HL60; HT_HG-U133A	ACACB LSS WIPI1	6.24e-04	194	20	3	2391_UP
Drug	Metergoline [17692-51-2]; Up 200; 10uM; HL60; HG-U133A	SUGP1 LSS WIPI1	6.24e-04	194	20	3	1606_UP
Drug	Hydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; HL60; HT_HG-U133A	ACACB WIPI1 GALNT2	6.24e-04	194	20	3	2430_DN
Drug	Aztreonam [78110-38-0]; Down 200; 9.2uM; PC3; HT_HG-U133A	ACACB SUGP1 ATP9B	6.24e-04	194	20	3	2118_DN
Drug	Raloxifene hydrochloride [82640-04-8]; Up 200; 7.8uM; MCF7; HT_HG-U133A	SUGP1 LSS WIPI1	6.33e-04	195	20	3	6235_UP
Drug	Oxethazaine [126-27-2]; Up 200; 8.6uM; HL60; HG-U133A	LSS ELOVL6 ACACA	6.33e-04	195	20	3	1984_UP
Drug	Betulin [473-98-3]; Down 200; 9uM; MCF7; HT_HG-U133A	MAP3K20 SUGP1 ATP9B	6.33e-04	195	20	3	3513_DN
Drug	Cefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; PC3; HT_HG-U133A	ACACB SUGP1 ATP9B	6.33e-04	195	20	3	7385_DN
Drug	N6-methyladenosine [1867-73-8]; Up 200; 14.2uM; HL60; HT_HG-U133A	SUGP1 ATP9B GALNT2	6.33e-04	195	20	3	1271_UP
Drug	felodipine; Down 200; 10uM; MCF7; HT_HG-U133A_EA	SUGP1 LSS ACACA	6.43e-04	196	20	3	848_DN
Drug	Promazine hydrochloride [53-60-1]; Down 200; 12.4uM; MCF7; HT_HG-U133A	MAP3K20 ACACB SUGP1	6.43e-04	196	20	3	6028_DN
Drug	Fluvoxamine maleate [61718-82-9]; Up 200; 9.2uM; MCF7; HT_HG-U133A	SUGP1 LSS ATP9B	6.43e-04	196	20	3	4114_UP
Drug	Nomifensine maleate [32795-47-4]; Down 200; 11.2uM; PC3; HT_HG-U133A	ACACB SUGP1 ELOVL6	6.43e-04	196	20	3	5863_DN
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A	SUGP1 LSS WIPI1	6.43e-04	196	20	3	5307_UP
Drug	Cefotaxime sodium salt [64485-93-4]; Up 200; 8.4uM; PC3; HT_HG-U133A	ACACB SUGP1 ELOVL6	6.43e-04	196	20	3	2072_UP
Drug	Paclitaxel [33069-62-4]; Up 200; 4.6uM; MCF7; HT_HG-U133A	LSS ATP9B WIPI1	6.43e-04	196	20	3	5320_UP
Drug	Amphotericin B [1397-89-3]; Down 200; 4.4uM; HL60; HT_HG-U133A	MAP3K20 ACACB LSS	6.43e-04	196	20	3	2441_DN
Drug	Diazoxide [364-98-7]; Up 200; 17.4uM; PC3; HT_HG-U133A	ACACB SUGP1 ELOVL6	6.43e-04	196	20	3	2052_UP
Drug	Clozapine [5786-21-0]; Up 200; 12.2uM; HL60; HT_HG-U133A	SUGP1 ELOVL6 ACACA	6.43e-04	196	20	3	1289_UP
Drug	Propoxycaine hydrochloride [550-83-4]; Up 200; 12uM; PC3; HT_HG-U133A	ACACB LSS ATP9B	6.43e-04	196	20	3	7155_UP
Drug	Sulpiride [15676-16-1]; Up 200; 11.8uM; HL60; HG-U133A	SUGP1 ATP9B ELOVL6	6.43e-04	196	20	3	1967_UP
Drug	Fenspiride hydrochloride [5053-08-7]; Down 200; 13.4uM; PC3; HT_HG-U133A	MAP3K20 SUGP1 ATP9B	6.43e-04	196	20	3	7298_DN
Drug	Terconazole [67915-31-5]; Up 200; 7.6uM; MCF7; HT_HG-U133A	ACACB LSS ATP9B	6.43e-04	196	20	3	4407_UP
Drug	Hexestrol [84-16-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A	SUGP1 LSS ATP9B	6.52e-04	197	20	3	6077_DN
Drug	Benserazide hydrochloride [14919-77-8]; Up 200; 13.6uM; PC3; HT_HG-U133A	SUGP1 DOCK2 LSS	6.52e-04	197	20	3	6722_UP
Drug	1-phenylbiguanide hydrochloride; Up 200; 10uM; MCF7; HG-U133A	SUGP1 WIPI1 ACACA	6.52e-04	197	20	3	22_UP
Drug	Bezafibrate [41859-67-0]; Up 200; 11uM; HL60; HT_HG-U133A	SUGP1 LSS GALNT2	6.52e-04	197	20	3	1275_UP
Drug	Fenofibrate [49562-28-9]; Up 200; 11uM; HL60; HT_HG-U133A	SUGP1 ATP9B WIPI1	6.52e-04	197	20	3	2401_UP
Drug	Hecogenin [467-55-0]; Down 200; 9.2uM; HL60; HT_HG-U133A	SUGP1 LSS WIPI1	6.52e-04	197	20	3	2716_DN
Drug	Betahistine mesylate [54856-23-4]; Down 200; 17.2uM; PC3; HT_HG-U133A	MAP3K20 ACACB SUGP1	6.52e-04	197	20	3	6611_DN
Drug	rosiglitazone; Down 200; 10uM; MCF7; HT_HG-U133A	SUGP1 ATP9B ELOVL6	6.52e-04	197	20	3	1658_DN
Drug	Phenylpropanolamine hydrochloride [154-41-6]; Up 200; 21.4uM; HL60; HG-U133A	ATP9B WIPI1 GALNT2	6.52e-04	197	20	3	1602_UP
Drug	PNU-0230031 [267429-39-0]; Down 200; 10uM; MCF7; HT_HG-U133A	ACACB SUGP1 WIPI1	6.52e-04	197	20	3	3629_DN
Drug	Allantoin [97-59-6]; Up 200; 25.2uM; HL60; HT_HG-U133A	ACACB SUGP1 WIPI1	6.52e-04	197	20	3	1842_UP
Drug	Ifenprodil tartrate [23210-58-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	SUGP1 ATP9B GALNT2	6.52e-04	197	20	3	5463_DN
Drug	Pheniramine maleate [132-20-7]; Up 200; 11.2uM; MCF7; HT_HG-U133A	ACACB SUGP1 LSS	6.52e-04	197	20	3	4130_UP
Drug	Sulfaguanidine [57-67-0]; Down 200; 18.6uM; PC3; HG-U133A	SUGP1 ATP9B GALNT2	6.62e-04	198	20	3	1913_DN
Drug	Methyldopa (L,-) [555-30-6]; Down 200; 19uM; HL60; HG-U133A	ELOVL6 GALNT2 ACACA	6.62e-04	198	20	3	1619_DN
Drug	Rilmenidine hemifumarate [54187-04-1]; Down 200; 8.4uM; MCF7; HT_HG-U133A	MAP3K20 SUGP1 ATP9B	6.62e-04	198	20	3	5532_DN
Drug	Kanamycin A sulfate [25389-94-0]; Down 200; 6.8uM; HL60; HG-U133A	SUGP1 GALNT2 ACACA	6.62e-04	198	20	3	1609_DN
Drug	Nicardipine hydrochloride [54527-84-3]; Down 200; 7.8uM; PC3; HT_HG-U133A	MAP3K20 ACACB SUGP1	6.62e-04	198	20	3	6297_DN
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Up 200; 7.8uM; HL60; HT_HG-U133A	SUGP1 LSS GALNT2	6.62e-04	198	20	3	1288_UP
Drug	Prednisone [53-03-2]; Up 200; 11.2uM; PC3; HG-U133A	ACACB ATP9B WIPI1	6.62e-04	198	20	3	1897_UP
Drug	Triamterene [396-01-0]; Up 200; 15.8uM; HL60; HT_HG-U133A	ACACB SUGP1 ATP9B	6.62e-04	198	20	3	1861_UP
Drug	Articaine hydrochloride [23964-57-0]; Down 200; 12.4uM; PC3; HT_HG-U133A	ACACB SUGP1 WIPI1	6.62e-04	198	20	3	7272_DN
Drug	ionomycin calcium salt; Down 200; 2uM; MCF7; HT_HG-U133A_EA	MAP3K20 SUGP1 LSS	6.62e-04	198	20	3	871_DN
Drug	Nafronyl oxalate [3200-06-4]; Down 200; 8.4uM; PC3; HT_HG-U133A	ACACB ATP9B ELOVL6	6.62e-04	198	20	3	6687_DN
Drug	Ketoprofen [22071-15-4]; Up 200; 15.8uM; HL60; HT_HG-U133A	SUGP1 CLDN18 ACACA	6.72e-04	199	20	3	2354_UP
Drug	Trichlorfon [52-68-6]; Up 200; 15.6uM; HL60; HT_HG-U133A	ACACB SUGP1 LSS	6.72e-04	199	20	3	1839_UP
Drug	gadolinium	CACNA1S ST8SIA1 ELOVL6	6.72e-04	199	20	3	CID000023982
Drug	Cephalothin sodium salt [58-71-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A	ACACB SUGP1 ATP9B	6.72e-04	199	20	3	6079_DN
Drug	Heliotrine [303-33-3]; Up 200; 12.8uM; MCF7; HT_HG-U133A	ACACB CLDN18 LSS	6.72e-04	199	20	3	3615_UP
Drug	DNA-PK Inhibitor III; Down 200; 1uM; PC3; HT_HG-U133A	MAP3K20 ACACB ELOVL6	6.72e-04	199	20	3	7548_DN
Drug	5230742; Down 200; 17uM; MCF7; HT_HG-U133A_EA	SUGP1 ELOVL6 ACACA	6.72e-04	199	20	3	862_DN
Drug	Cefuroxime sodium salt [56238-63-2]; Down 200; 9uM; MCF7; HT_HG-U133A	ACACB SUGP1 ATP9B	6.72e-04	199	20	3	6088_DN
Disease	muscular disease (implicated_via_orthology)	ACACB ACACA	5.30e-06	5	22	2	DOID:0080000 (implicated_via_orthology)
Disease	cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement	ACACB WIPI1 GALNT2 AZIN1	4.80e-05	276	22	4	EFO_0004612, EFO_0020943
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	6.60e-05	106	22	3	EFO_0008317, EFO_0008596
Disease	free cholesterol measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	7.37e-05	110	22	3	EFO_0008317, EFO_0008591, EFO_0008596
Disease	cholesteryl ester measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	7.37e-05	110	22	3	EFO_0008317, EFO_0008596, EFO_0010351
Disease	chylomicron measurement, total cholesterol measurement, very low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	7.37e-05	110	22	3	EFO_0004574, EFO_0008317, EFO_0008596
Disease	Lipoidosis	LSS WIPI1	9.00e-05	19	22	2	C0023794
Disease	triglyceride measurement, phospholipid measurement	ACACB SUGP1 GALNT2	1.71e-04	146	22	3	EFO_0004530, EFO_0004639
Disease	fatty liver disease (implicated_via_orthology)	ACACB ACACA	2.44e-04	31	22	2	DOID:9452 (implicated_via_orthology)
Disease	triglyceride measurement, low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	2.49e-04	166	22	3	EFO_0004530, EFO_0004611
Disease	low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	ACACB SUGP1 GALNT2	4.30e-04	200	22	3	EFO_0004611, EFO_0020945
Disease	triglycerides:total lipids ratio, high density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	4.68e-04	206	22	3	EFO_0004612, EFO_0020947
Disease	triglycerides in large LDL measurement	SUGP1 GALNT2	4.70e-04	43	22	2	EFO_0022319
Disease	free cholesterol measurement, very low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	5.30e-04	215	22	3	EFO_0008317, EFO_0008591
Disease	very low density lipoprotein cholesterol measurement, lipid measurement	ACACB SUGP1 GALNT2	5.67e-04	220	22	3	EFO_0004529, EFO_0008317
Disease	triglyceride measurement, very low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	5.98e-04	224	22	3	EFO_0004530, EFO_0008317
Disease	total cholesterol measurement, very low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	5.98e-04	224	22	3	EFO_0004574, EFO_0008317
Disease	phospholipids:total lipids ratio	SUGP1 WIPI1 GALNT2	6.21e-04	227	22	3	EFO_0020946
Disease	very low density lipoprotein cholesterol measurement, phospholipid measurement	ACACB SUGP1 GALNT2	6.37e-04	229	22	3	EFO_0004639, EFO_0008317
Disease	diglyceride measurement	SUGP1 GALNT2	6.62e-04	51	22	2	EFO_0010223
Disease	cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	7.57e-04	243	22	3	EFO_0004612, EFO_0020944
Disease	alkaline phosphatase measurement	ACACB SUGP1 WIPI1 ELOVL6 AZIN1	7.71e-04	1015	22	5	EFO_0004533
Disease	triglycerides in LDL measurement	SUGP1 GALNT2	7.98e-04	56	22	2	EFO_0022320
Disease	triglycerides in very large VLDL measurement	SUGP1 GALNT2	7.98e-04	56	22	2	EFO_0022325
Disease	triglycerides to total lipids in medium HDL percentage	SUGP1 GALNT2	7.98e-04	56	22	2	EFO_0022333
Disease	triglycerides in chylomicrons and extremely large VLDL measurement	SUGP1 GALNT2	7.98e-04	56	22	2	EFO_0022316
Disease	triglycerides in IDL measurement	SUGP1 GALNT2	8.55e-04	58	22	2	EFO_0022149
Disease	triglycerides in VLDL measurement	SUGP1 GALNT2	8.85e-04	59	22	2	EFO_0022326
Disease	concentration of chylomicrons and extremely large VLDL particles measurement	SUGP1 GALNT2	8.85e-04	59	22	2	EFO_0022260
Disease	cholesterol to total lipids in medium HDL percentage	SUGP1 GALNT2	9.15e-04	60	22	2	EFO_0022237
Disease	cholesterol in chylomicrons and extremely large VLDL measurement	SUGP1 GALNT2	9.15e-04	60	22	2	EFO_0021898
Disease	very low density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	9.20e-04	260	22	3	EFO_0008317
Disease	free cholesterol in very large VLDL measurement	SUGP1 GALNT2	9.46e-04	61	22	2	EFO_0022274
Disease	triglycerides in small VLDL measurement	SUGP1 GALNT2	9.46e-04	61	22	2	EFO_0022145
Disease	triglycerides in medium LDL measurement	SUGP1 GALNT2	9.77e-04	62	22	2	EFO_0022322
Disease	triglycerides to total lipids in very large HDL percentage	SUGP1 GALNT2	9.77e-04	62	22	2	EFO_0022339
Disease	triglycerides in small HDL measurement	SUGP1 GALNT2	9.77e-04	62	22	2	EFO_0022158
Disease	free cholesterol in chylomicrons and extremely large VLDL measurement	SUGP1 GALNT2	9.77e-04	62	22	2	EFO_0022263
Disease	phospholipids in very large VLDL measurement	SUGP1 GALNT2	9.77e-04	62	22	2	EFO_0022299
Disease	total lipids in chylomicrons and extremely large VLDL measurement	SUGP1 GALNT2	9.77e-04	62	22	2	EFO_0022306
Disease	total lipids in very large VLDL measurement	SUGP1 GALNT2	9.77e-04	62	22	2	EFO_0022313
Disease	free cholesterol to total lipids in medium LDL percentage	SUGP1 GALNT2	1.01e-03	63	22	2	EFO_0022283
Disease	phospholipids in chylomicrons and extremely large VLDL measurement	SUGP1 GALNT2	1.01e-03	63	22	2	EFO_0022292
Disease	triglyceride measurement, high density lipoprotein cholesterol measurement	ACACB SUGP1 GALNT2	1.07e-03	274	22	3	EFO_0004530, EFO_0004612
Disease	non-alcoholic fatty liver disease (biomarker_via_orthology)	ACACB ACACA	1.07e-03	65	22	2	DOID:0080208 (biomarker_via_orthology)
Disease	triglycerides in small LDL measurement	SUGP1 GALNT2	1.07e-03	65	22	2	EFO_0022323
Disease	triglycerides to phosphoglycerides ratio	SUGP1 GALNT2	1.17e-03	68	22	2	EFO_0022327
Disease	triglycerides in very small VLDL measurement	SUGP1 GALNT2	1.17e-03	68	22	2	EFO_0022144
Disease	apolipoprotein B measurement	ACACB SUGP1 KCTD6 GALNT2	1.34e-03	663	22	4	EFO_0004615
Disease	nucleotide measurement	DOCK2 GALNT2	1.35e-03	73	22	2	EFO_0010513
Disease	phospholipids:total lipids ratio, high density lipoprotein cholesterol measurement	WIPI1 GALNT2 AZIN1	1.48e-03	307	22	3	EFO_0004612, EFO_0020946

Protein segments in the cluster

Peptide	Gene	Start	Entry
MMSFSDWYEMQDAGI	AZIN1	406	O14977
WRGFSGGMKDMYDQV	ACACA	2046	Q13085
DMNGFQQEGFGWMDM	CHDH	216	Q8NE62
NWRGFSGGMKDMYDQ	ACACB	2156	O00763
GKAVYGWMMMKDENI	ATP9B	431	O43861
LGKYDMMMDVWGGEN	GALNT2	321	Q10471
AGKGYLWKAAGMNME	EIF2B5	491	Q13144
PDYLWMGLDGMKMQG	LSS	366	P48449
YKDMVAGGGWFMTMN	ELOVL6	156	Q9H5J4
GKNVYPGDWMAMSMV	DOCK2	981	Q92608
WTSMMYNGIMAYGGP	CACNA1S	616	Q13698
GPQDCKWKMYMEMDG	MAP3K20	451	Q9NYL2
MDNGDWGYMMTDPVT	KCTD6	1	Q8NC69
EPFGYMGMVWAMMSI	MT-CO1	266	P00395
MGMVWAMMSIGFLGF	MT-CO1	271	P00395
NFWMSTANMYTGMGG	CLDN18	146	P56856
NGAMMDVWDAHYKMF	DSEL	621	Q8IZU8
KMNSPMGKSMWYDGE	ST8SIA1	96	Q92185
MGGKMEATPFKWFME	PI4KAP2	491	A4QPH2
TVENIGYQMLMKMGW	SUGP1	561	Q8IWZ8
GYQMLMKMGWKEGEG	SUGP1	566	Q8IWZ8
MGHDKMYWYQQDPGM	TRB	46	P0DTU4
MGHDKMYWYQQDPGM	TRBV25-1	46	A0A075B6N4
MWGAFLLYVSMKMGG	TRAV1-1	1	A0A0B4J248
EPSTWSGYMGKMFMA	WIPI1	271	Q5MNZ9
MWGVFLLYVSMKMGG	TRAV1-2	1	A0A0B4J238